Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1027 of 5804
-
Parkinson's patients try VR to stay steady on their feet
Symptom relief Not yet recruitingThe goal of this clinical trial is to evaluate whether immersive virtual reality (VR)-based physiotherapy is effective in improving balance, reducing fall risk, and enhancing cardiorespiratory exercise capacity in individuals with Parkinson's disease. The main questions it aims t…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Could a simple kit ease sexual pain for millions with endometriosis?
Symptom relief Recruiting nowEndometriosis is a complex gynecological condition that affects approximately 10% of women of reproductive age, according to 2023 data from the World Health Organization. Endometriosis is often associated with debilitating pain, particularly during sexual intercourse (dyspareunia…
Phase: NA • Sponsor: Elsan • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug SLN12140 aims to control kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis study is a randomized, parallel, double-blind, placebo-controlled, subcutaneous administration Phase II dose-exploration clinical trial aimed at evaluating the efficacy, safety, PK, PD, and immunogenicity characteristics of SLN12140 at different doses in IgA nephropathy subj…
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
One-Shot gene therapy could simplify cancer treatment
Disease control Recruiting nowThis is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of IASO207 Injection in patients with Relapsed/Refractory B-cell Malignancies。
Phase: EARLY_PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New immune drug takes on Hard-to-Treat cancers
Disease control Not yet recruitingThis is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A\*02:01-positive and MAGE-A1-positive advanced solid tumors. The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and …
Phase: PHASE1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Laser therapy aims to preserve sight in AMD patients
Disease control Recruiting nowThe goal of this study is to demonstrate that photothermal therapy with the individually dosed treatment plan proposed by Macula Explorer delivered safely by Navilas® Laser System effectively improves the life of photoreceptors and reduces the progression of intermediate Age-rela…
Phase: NA • Sponsor: OD-OS MacuTherm GmbH • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
One shot to tackle two heart risks? new combo drug enters human trials
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hyperc…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Gene therapy for Parkinson's: will it last? new study tracks 6 patients over time
Disease control Recruiting nowThe purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Sponsor: Innopeutics Corporation • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study is a Phase Ib/II clinical study. It includes two stages: Phase Ib and Phase II. In the Phase Ib stage, the primary objective is to evaluate the safety and tolerability of SYS6006 in combination with Enlonstobart Injection in participants with advanced solid tumors, and…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo aims to stop kidney rejection in its tracks
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft injury. Participants will be followed …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New triple inhaler could simplify asthma care for teens
Disease control Not yet recruitingA double-dummy, double-blind, randomized, parallel-group, active controlled study to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill targets Hard-to-Treat cancer mutation in early human test
Disease control Recruiting nowThis is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.
Phase: PHASE1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThe purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Phase: PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Caffeine boost may shield preterm Babies' kidneys
Disease control Recruiting nowThis study is being done to see if additional caffeine citrate (20 milligrams per kilogram IV bolus) helps babies with low kidney oxygenation already being treated with caffeine citrate (20 milligrams per kilogram IV bolus on day of life (DOL) 1 followed by 8 milligrams per kilog…
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Supercharged cord blood cells take on resistant blood cancers
Disease control Recruiting nowThis is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Spinal zaps and drug combo aim to boost mobility in kids with cerebral palsy
Disease control Recruiting nowThis is an intervention study to investigate the impact of spinal stimulation on mobility outcomes in children with Cerebral Palsy. Participants will complete a 16-week training program with weekly sessions of spinal stimulation and walking or activity-based training. Participant…
Phase: PHASE2 • Sponsor: Shirley Ryan AbilityLab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill could help shed pounds: obesity drug trial begins
Disease control Recruiting nowThe primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.
Phase: PHASE2 • Sponsor: ERX Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill hopes to tame severe gut disease in kids
Disease control Recruiting nowThe purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to \< 12 years of age). Participants who will complete the total 5…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could less radiation be better for prostate cancer?
Symptom relief Recruiting nowThe purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effects compared to giving the same (uniform) dose of radiation therapy to the whole prostate.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC